Here is the design of a clinical trial:

Official Title: Escitalopram and Language Intervention for Subacute Aphasia (ELISA)

Included conditions:
- Aphasia
- Stroke

Study Armgroups:
- {'label': 'Naming Treatment + Escitalopram', 'type': 'EXPERIMENTAL', 'description': '10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)', 'interventionNames': ['Drug: Escitalopram 10mg', 'Behavioral: Computer-delivered naming treatment']}
- {'label': 'Naming Treatment + Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': '10 mg placebo daily for three months', 'interventionNames': ['Drug: Placebo', 'Behavioral: Computer-delivered naming treatment']}

Interventions:
- {'type': 'DRUG', 'name': 'Escitalopram 10mg', 'description': 'Escitalopram tablet', 'armGroupLabels': ['Naming Treatment + Escitalopram'], 'otherNames': ['Lexapro']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Sugar pill manufactured to mimic escitalopram 10 mg tablet', 'armGroupLabels': ['Naming Treatment + Placebo'], 'otherNames': ['Placebo (for Escitalopram)']}
- {'type': 'BEHAVIORAL', 'name': 'Computer-delivered naming treatment', 'description': '15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke', 'armGroupLabels': ['Naming Treatment + Escitalopram', 'Naming Treatment + Placebo'], 'otherNames': ['Computer-delivered naming treatment (CoDeNT)']}

Primary Outcomes:
- {'measure': 'Change in Philadelphia Naming Test short-form accuracy score', 'description': 'Number of correctly named items of 30 total items on the computerized picture naming assessment. Scores ranges from 0 to 30 with higher scores meaning better naming ability.', 'timeFrame': 'Baseline, 1 week after computer-delivered naming treatment'}

Please estimate the sample size based on the assumption: 
The study is designed with a significance level (Î±) of 0.05, one-tailed, and 90% power. An attrition or non-compliance rate of up to 20% is anticipated, leading to an inflation factor of R = 1/(1-0.20)^2.
Sample size estimates
        Eighty-eight participants are expected to enroll in this study. We expect at least 56 will complete the study on the study drug. However, all participants randomized will be included in the intent-to-treat analysis. A final sample size of 28 per group has 90% power to detect an effect size of d = 0.8 using a t-test with Î± = 0.05, one-tailed. The planned sample size was inflated from N = 56 to N = 88 to account for up to 20% attrition or non-compliance, using an inflation factor of R = 1/(1â0.20)2. Effect sizes >1 in naming improvements amongst post-stroke patients who took SSRIs for three months SSRIs have been reported [7]; however, we have conservatively powered this study for a smaller effect.
        We predict no difficulty recruiting at least 22 people with aphasia due to acute stroke each year. The PI has recruited an average of 13 people with aphasia due to acute left hemisphere ischemic stroke each year in her ongoing treatment study with tDCS at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, with similar inclusion and exclusion criteria. We anticipate having more difficulty enrolling in this trial, because of the exclusion criteria of moderately-severe depression or use of SSRIs at the time of stroke. We also plan for a relatively high dropout rate/crossovers, because of the risk of developing moderate-severe depression or other events for which stroke patients are at risk (e.g. recurrent stroke) and a small risk of developing prolonged QTc interval on electrocardiogram on escitalopram.